2. Parker, P. J., Parkinson, S. J. (2001). AGC protein kinasesphosphorylation and protein kinase C. Biochem. Soc. Trans. 29, 860 –863.

(1)

BIBLIOGRAFIA

(2)

60 Trends Mol. Med. 8, S14 – S18.

2. Parker, P. J., Parkinson, S. J. (2001). AGC protein kinasesphosphorylation and protein kinase C. Biochem. Soc. Trans. 29, 860 –863.

3. Harris T.K. (2003). PDK1 and PKB/Akt: Ideal Targets for Development of New Strategies to Structure-Based Drug Design. Life, 55(3): 117–126.

4. Staal S.P. (1987). Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA; 84:5034-7.

5. Gonzalez E., McGraw T.E. (2009). The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 15; 8(16): 2502–2508.

6. Datta K., Bellacosa A., Chan T.O., Tsichlis P.N. (1996). Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha- ras, in Sf9 and mammalian cells. J Biol Chem. 29;271(48):30835-9.

7. Liu A.X., Testa J.R., Hamilton T.C., Jove R., Nicosia S.V., Cheng J.Q. (1998).

AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res. 15;58(14):2973-7.

8. Sun M., Yang L., Feldman R.I., Sun X.M., Bhalla K.N., Jove R., Nicosia S.V., Cheng J.Q. (2003). Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem. 31;278(44):42992-3000.

9. Altomare D.A., Testa J.R. (2005) “Perturbations of the AKT signaling pathway in human cancer” Oncogene24,7455–7464

10. Testa J.R., Bellacosa A. (2001). AKT plays a central role in tumorigenesis. Proc

Natl Acad Sci U S A.;98(20):10983-5.

(3)

61 11. Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., Coppola D., Nicosia S.V., Cheng J.Q. .(2000) Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer; Oncogene 19,2324-30.

12. George S., Rochford J.J., Wolfrum C., Gray S.L., Schinner S., Wilson J.C., Soos M.A., Murgatroyd P.R., Williams R.M., Acerini C.L., Dunger D.B., Barford D., Umpleby A.M., Wareham N.J., Davies H.A., Schafer A.J., Stoffel M., O'Rahilly S., Barroso I. (2004). A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science Vol. 304 no. 5675 pp. 1325-1328

13. Cheng J.Q., Lindsley CW, Cheng GZ, Yang H, Nicosia SV. (2005). The Akt/PKB pathway: molecular target for cancer drug discovery.

Oncogene;24(50):7482-92. Review

14. Thomas C.C., Deak M., Alessi D.R., van Aalten D.M. (2002). High resolution structure of the PH domain of PKB/Akt boun to phosphetidylinositol (3,4,5)- triphosphate. Curr.Biol., 12, 1256-1262

15. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., and Cohen P. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997;7:261–9.

16. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. ( (2005).

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Science; 307:1098–101.

17. Toker A. and Newton A.C. (2000). Cellular signaling: pivoting around PDK1.

Cell, 103, 185-188.

(4)

62 small molecular inhibitors and progress Towards Target Validation: a 2009 update. Current Topics in Medicinal Chemistry, 10, 458-477(20).

19. Falasca M. (2010). PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs. Current Pharmaceutical Design, 16, 12, 1410-1416(7).

20. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., et al (2004). Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.

Nature 18;428(6980):332-7.

21. Cantley L.C., Neel B.G. (1999).New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A.;96(8):4240-5.

22. Hay N., Sonenberg N. (2004). "Upstream and downstream of mTOR". Genes Dev 18(16): 1926–45. doi:10.1101/gad.1212704. PMID 15314020.

23. Feldman R.I., Wu J.M., Polokoff M.A., Kochanny M.J., Dinter H., Zhu D., Biroc S.L., Alicke B., Bryant J., Yuan S., Buckman B.O., Lentz D., Ferrer M., Whitlow M., Adler M., Finster S., Chang Z., Arnaiz D.O. (2005). Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem.

280(20):19867-74.

24. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J.;408(3):297-315.

25. Islam I., Brown G., Bryant J., Hrvatin P., Kochanny M.J., Phillips G.B., Yuan S., Adler M., Whitlow M., Lentz D., Polokoff M.A., Wu J., Shen J., Walters J., Ho E., Subramanyam B., Zhu D., Feldman R.I., Arnaiz D.O. (2007). Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2:

optimization of BX-517. Bioorg Med Chem Lett.;17(14):3819-25.

(5)

63 26. Wymann M.P., Bulgarelli-Leva G., Zvelebil M.J., Pirola L., Vanhaesebroeck B., Waterfield M.D., Panayotou G. (1996). Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol.;16(4):1722-33.

27. Wetzker R., Rommel C. (2004) Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr Pharm Des.;10(16):1915-22.

28. Semba S., Itoh N., Ito M., Youssef E.M., Harada M., Moriya T., Kimura W., Yamakawa M. (2002). Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma. Clin Cancer Res. 2002 Dec;8(12):3824-31.

29. Stauffer F., Holzer P., García-Echeverría C. (2005) Blocking the PI3K/PKB pathway in tumor cells. Curr Med Chem Anticancer Agents.;5(5):449-62.

30. Li Q. (2007). Recent progress in the discovery of Akt inhibitors as anticancer agents Expert Opin. Ther. Patents, 17(9):1077-1130.

31. ASTEX: WO05011697 ( 2005 ).

32. Li Q., Li T.., Zhu G.D. et al. ( 2006 ). Discovery of trans -3,4′- bis pyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: synthesis and biological evaluation. Bioorg. Med.

Chem. Lett. 16 : 1679 -1685.

33. Zhu G.D., Gandhi V.B., Gong J., Luo Y., Liu X., Shi Y., Guan R., Magnone

S.R., Klinghofer V., Johnson E.F., Bouska J., Shoemaker A., Oleksijew A.,

Jarvis K., Park C., Jong R.D., Oltersdorf T., Li Q., Rosenberg S.H., Giranda

V.L. (2006) Discovery and SAR of oxindole-pyridine-based protein kinase

B/Akt inhibitors for treating cancers. Bioorg Med Chem Lett. 1;16(13):3424-9.

(6)

64 Li M., Safonov I.G., Takata D.T., Venslavsky J.W., Yamashita D.S., Choudhry A.E., Copeland R.A., Lai Z., Schaber M.D., Tummino P.J., Strum S.L., Wood E.R., Duckett D.R., Eberwein D., Knick V.B., Lansing T.J., McConnell R.T., Zhang S., Minthorn E.A., Concha N.O., Warren G.L., Kumar R.(2008) Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3- piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.J Med Chem.;51(18):5663-79.

35. Rouse M.B., Seefeld M.A., Leber J.D., McNulty K.C., Sun L., Miller W.H., Zhang S., Minthorn E.A., Concha N.O., Choudhry A.E., Schaber M.D., Heerding D.A.(2009) Aminofurazans as potent inhibitors of AKT kinase. Bioorg Med Chem Lett.1;19(5):1508-11.

36. Kumar R., Rhodes N., Knick V.b. et al. ( 2007 ). Gsk690693, a pan-Akt kinase inhibitor has potent anti-tumor activity and shows additive effect with lapatinib.

Annual meeting of American Association for Cancer Research . Los Angeles, Usa:(Abstract 279).

37. ASTEX: WO05061463 ( 2005 )

38. ASTEX: WO06136823 ( 2006 ).

39. ASTEX: WO06136830 ( 2006 ).

40. ASTEX: GB2427406 ( 2005 ).

41. NOVARTIS: WO05054237 ( 2005 ).

42. Gills J.J., Dennis P.A.( 2004). The development of phosphatidylinositol ether

lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin

Investig Drugs.;13(7):787-97.

(7)

65 43. Hu Y., Qiao L., Wang S., Rong S.B., Meuillet E.J., Berggren M., Gallegos A., Powis G., Kozikowski A.P. (2000) 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem.;43(16):3045-51.

44. Molinedo F. (2007).Antitumour ether lipids: proapoptotic agents with multiple therapeutic indications, Vol. 17, No. 4 , Pages 385-405.

45. Barnett S.F., Defeo-Jones D., Fu S., Hancock P.J., Haskell K.M., Jones R.E., Kahana J.A., Kral A.M., Leander K., Lee L.L., Malinowski J., McAvoy E.M., Nahas D.D., Robinson R.G., Huber H.E. (2005). Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme- specific Akt inhibitors.Biochem J.;385(Pt 2):399-408.

46. DeFeo-Jones D., Barnett S.F., Fu S., Hancock P.J., Haskell K.M., Leander K.R., McAvoy E., Robinson R.G., Duggan M.E., Lindsley C.W., Zhao Z., Huber HE, Jones R.E. (2005) Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther.;4(2):271-9.

47. MERCK: US20040102360 ( 2004 ).

48. Peifer C., Alessi D.R. (2008). Small-molecule inhibitors of PDK1.

ChemMedChem. Dec;3(12):1810-38.

49. Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., and Tang C. (1998).

Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel

Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular

Receptor Tyrosine Kinases. J. Med. Chem., 41 (14), pp 2588–2603